

# A phase 2 multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

ATG responsive

T-cell-mediated  
bone marrow injury

transitional period  
for T-cell function

23 months

ATG non-responsive

T-cell-mediated  
anti-tumor immunity



duration of disease

variables favoring ATG response

shorter disease duration  
% Ki67 on CD4<sup>+</sup> T-cells  
% terminal memory CD8<sup>+</sup> cells

variables associated with ATG failure

longer disease duration  
bone marrow fibrosis  
more than 2 prior MDS therapies